Implantica AG (IMPASDB) Earnings Call Transcripts

Implantica AG's Latest Earnings Call - Q1 FY2026

In Q1 2026, Implantica AG reported net sales of EUR 857,000, a 15% increase year-over-year, driven by the ongoing commercialization of its RefluxStop product. The company achieved an adjusted gross margin of 93% and improved its operating loss to EUR 3.9 million, reflecting disciplined cost management. Management expressed optimism regarding FDA approval for RefluxStop, with a potential launch in the U.S. anticipated within 90 days, which could significantly accelerate revenue growth in the coming quarters.

Reported metrics

Guidance from management

Management is optimistic about achieving U.S. FDA approval within 90 days, which could significantly accelerate revenue growth. They expect constant expansion in Europe as reimbursement situations improve.

What management said

No, I think the increase is because this -- to sell in the study format cost us money. And we have hold down a little bit. So the expansion you see, that's mainly the real the real money, so to say, the real sales of products that is expanding. And you see that in Italy, for example, you saw it's quite a lot of different tender wins. And also in Spain, the same, it's -- we were step-by-step getting that.

I mean, this is a good question. We have actually filed to [indiscernible] also now. We have an application already [indiscernible] that they should approve it based on the surgeries we have one. And we don't know the outcome of that, but there is a certain likelihood that it will be now this year and that we then need to come back to next year. But all these other organizations, it's very difficult for us to promise...

What analysts pressed on

Analysts expressed concerns regarding the timeline for FDA approval and subsequent reimbursement processes in the U.S. There were questions about the potential delays in launching and the need for training surgeons before the product can be widely adopted.

Main topics on the call

• FDA Submission and Approval Process — Management confirmed that all three PMA modules have been reviewed by the FDA, stating, "everything is under control" regarding the remaining requirements. They anticipate a response within 90 days, potentially leading t...
• Revenue Growth and Commercialization — Implantica reported a 15% year-over-year increase in net sales, totaling EUR 857,000. CEO Peter Forsell noted that the increase is due to real sales of products, stating, "the expansion you see, that's mainly the real mo...
• Cost Management and Financial Position — The company achieved an adjusted gross margin of 93% and improved its operating loss by 8% year-on-year. CFO Andreas Öhrnberg highlighted a 19% improvement in operating cash outflow, indicating a solid financial position...
• Market Expansion Opportunities — Management noted the withdrawal of J&J's LINX device from markets outside the U.S., creating a significant opportunity for RefluxStop. Forsell stated, "our intention is to fill that gap," indicating a strategic focus on ...

Read the full Implantica AG transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 16 Implantica AG earnings call transcripts on record, spanning November 15, 2022 to May 22, 2026. Based on this history, Implantica AG reports quarterly. The most recent call on file is dated May 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IMPASDB

Exchange

OM

Country

SE

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

16

First call

November 15, 2022

Most recent

May 22, 2026

Reporting cadence

quarterly